Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BAX 855 phase 3b continuation prophylaxis study in severe hemophilia A
NL-OMON45192Phase 3Active, not recruiting
- Sponsor
- Baxalta
- Start
- Jun 2014
- Modality
- Recombinant Proteins and Enzymes, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 3, open-label trial of rurioctocog alfa pegol in hemophilia A (2 arms), sponsored by Baxalta. Primary endpoints: Development of inhibitory antibodies to factor VIII and Spontaneous annualized bleeding rate. Started Jun 2014; status: active, not recruiting.
02
Drugs
rurioctocog alfa pegol
03
Conditions
hemophilia A
Beyond the preview
Go deeper on NL-OMON45192.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON45192.